Modality
mAb
MOA
SGLT2i
Target
TIM-3
Pathway
Ferroptosis
HCCALS
Development Pipeline
Preclinical
Apr 2018
→ Oct 2031
PreclinicalCurrent
NCT05743984
2,600 pts·HCC
2018-04→2031-10·Terminated
NCT07233155
2,140 pts·ALS
2022-03→2030-07·Terminated
4,740 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-11-224mo agoFast Track· HCC
2030-07-034.3y awayInterim· ALS
2031-10-075.5y awayInterim· HCC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Termina…
Preclinical
Termina…
Catalysts
Fast Track
2025-11-22 · 4mo ago
HCC
Interim
2030-07-03 · 4.3y away
ALS
Interim
2031-10-07 · 5.5y away
HCC
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05743984 | Preclinical | HCC | Terminated | 2600 | Safety |
| NCT07233155 | Preclinical | ALS | Terminated | 2140 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |